Try our Advanced Search for more refined results
ScieGen Pharmaceuticals Inc.
-
Utility | Filed: May 28, 2024 | Entered: May 28, 2024 In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation
Patent - Abbreviated New Drug Application(ANDA) | Delaware
- CORRECTING ENTRY
CORRECTING ENTRY: The Notice of Service (D.I. 271 in 21md3017-RGA; D.I. 50 in 23cv1103-RGA) filed on 5/24/2024, has been removed as it was duplicative of a a notice of service already on the docket. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01103-RGA(nms)
-
Discovery | Filed: May 24, 2024 | Entered: May 24, 2024 In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Notice of Service
NOTICE OF SERVICE of Defendants List of Claim Terms, Phrases and Proposed Constructions filed by Auson Pharmaceuticals, Inc., Shanghai Auson Pharmaceuticals Co. Ltd..(DeSantis, Kasey)
-
Discovery | Filed: May 24, 2024 | Entered: May 24, 2024 In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Notice of Service
NOTICE OF SERVICE of Defendants List of Claim Terms, Phrases and Proposed Constructions filed by Auson Pharmaceuticals, Inc., Shanghai Auson Pharmaceuticals Co. Ltd..(DeSantis, Kasey)
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login